Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer

Neoadjuvant chemotherapy (NAC) is used to treat triple-negative breast cancer (TNBC) prior to resection. Biomarkers that accurately predict a patient’s response to NAC are needed to individualise therapy and avoid chemotoxicity from unnecessary chemotherapy. We performed whole-genome DNA methylation...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Braydon, Clifton, Samuel, Locke, Warwick, Luu, Phuc-Loi, Du, Qian, Lam, Dilys, Armstrong, Nicola J., Kumar, Beena, Deng, Niantao, Harvey, Kate, Swarbrick, Alex, Ganju, Vinod, Clark, Susan J., Pidsley, Ruth, Stirzaker, Clare
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684655/
https://www.ncbi.nlm.nih.gov/pubmed/34922619
http://dx.doi.org/10.1186/s13148-021-01210-6
Descripción
Sumario:Neoadjuvant chemotherapy (NAC) is used to treat triple-negative breast cancer (TNBC) prior to resection. Biomarkers that accurately predict a patient’s response to NAC are needed to individualise therapy and avoid chemotoxicity from unnecessary chemotherapy. We performed whole-genome DNA methylation profiling on diagnostic TNBC biopsy samples from the Sequential Evaluation of Tumours Undergoing Preoperative (SETUP) NAC study. We found 9 significantly differentially methylated regions (DMRs) at diagnosis which were associated with response to NAC. We show that 4 of these DMRs are associated with TNBC overall survival (P < 0.05). Our results highlight the potential of DNA methylation biomarkers for predicting NAC response in TNBC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13148-021-01210-6.

Ejemplares similares